This document is a USPTO patent application (US20260078199A1) for "METHODS AND MATERIALS FOR ASSESSING RESPONSE TO PLASMABLAST- AND PLASMA CELL-DEPLETING THERAPIES." The application, filed on July 14, 2025, by inventors Glennda Smithson, Jose Estevam, and Nicholas Jones, relates to anti-CD38 antibodies and their use in treating autoimmune diseases like systemic lupus erythematosus and rheumatoid arthritis, as well as diagnostic methods for identifying patients with these conditions.

As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it signifies potential future developments in therapeutic and diagnostic technologies within the pharmaceutical and biotechnology sectors. Companies involved in the research and development of antibody-based therapies or diagnostics for autoimmune diseases should be aware of this filing as it may impact intellectual property landscapes and future product development strategies.